If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humalog Summary of Product Characteristics (SmPC)
Humalog 200 Units/ml (insulin lispro): Fertility pregnancy and lactation
Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/newborn
Pregnancy
Data
on a large number of exposed pregnancies do not indicate any adverse
effect of insulin lispro on pregnancy or on the health of the
foetus/newborn.
It
is essential to maintain good control of the insulin-treated
(insulin-dependent or gestational diabetes) patient throughout
pregnancy. Insulin requirements usually fall during the first
trimester and increase during the second and third trimesters.
Patients with diabetes should be advised to inform their doctor if
they are pregnant or are contemplating pregnancy. Careful monitoring
of glucose control, as well as general health, is essential in
pregnant patients with diabetes.
Breast-feeding
Patients
with diabetes who are breast-feeding may require adjustments in
insulin dose, diet or both.
Fertility
Insulin
lispro did not induce fertility impairment in animal studies.
Reference
Humalog
200 Units/ml [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.
Date of Last Review:December 26, 2018
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com